吲哚胺2,3双加氧酶在乳腺癌中的表达及其与预后的关系

目的 探讨吲哚胺2,3双加氧酶(IDO)在乳腺癌中的表达及其与乳腺癌临床病理特征、预后的关系.方法 收集40例乳腺癌蜡块,应用免疫组化SP法检测乳腺癌组织中IDO的表达,并对全部标本用CD31和CD105对肿瘤血管内皮细胞进行染色,计数肿瘤微血管密度(MVD),结合患者的临床病理特征及预后进行分析.结果 乳腺癌组织中IDO蛋白高表达率为67.5%(27/40),其表达与临床分期和淋巴结转移相关(均P＜0.05).IDO高表达组与低表达组的3年、 5年无瘤生存率差异均无统计学意义(P=0.211,P=0.523).乳腺癌组织中IDO表达与CD105标记的MVD值呈正相关(r=0.659,P＜0.05),与CD31标记的MVD值无关.结论 IDO可能通过促进新生血管形成加速乳腺癌的进展和转移,IDO表达与乳腺癌患者预后的关系需要进一步扩大样本量加以明确.

Abstract：

Objective To investigate the expression of indoleamine 2,3-dioxygenase (IDO) in breast cancer and its correlation with clinicopathologic factors and prognosis. Methods The expression of IDO, CD31, CD105 proteins in 40 specimens of breast cancer were assessed by immunohistochemistry. Results The overexpression rate of IDO in breast cancer was 67.5% (27/40), and expression of IDO was closely associated with clinical stage and lymph nodes metastasis. The disease-free survival rate in patients with IDO overexpression was not significantly lower than that in patients with negative or low expression of IDO(P>0.05). Moreover, the expression of IDO was positively correlated with CD105-labeled microvessel density (r=0.659,P<0.05). Conclusions Expression of IDO is associated with clinical stage and lymph nodes metastasis, and microvessel densitty. IDO expression may promote the growth and metastasis of breast cancer, probably via the increased agiogenesis. A larger sample study is needed to verify whether the prognosis of beast cancer is significantly correlated with IDO expression.

Expression of indoleamine 2, 3-dioxygenase and its correlation with prognosis in breast cancer patients

Objective To investigate the expression of indoleamine 2,3-dioxygenase (IDO) in breast cancer and its correlation with clinicopathologic factors and prognosis. Methods The expression of IDO, CD31, CD105 proteins in 40 specimens of breast cancer were assessed by immunohistochemistry. Results The overexpression rate of IDO in breast cancer was 67.5% (27/40), and expression of IDO was closely associated with clinical stage and lymph nodes metastasis. The disease-free survival rate in patients with IDO overexpression was not significantly lower than that in patients with negative or low expression of IDO(P>0.05). Moreover, the expression of IDO was positively correlated with CD105-labeled microvessel density (r=0.659,P<0.05). Conclusions Expression of IDO is associated with clinical stage and lymph nodes metastasis, and microvessel densitty. IDO expression may promote the growth and metastasis of breast cancer, probably via the increased agiogenesis. A larger sample study is needed to verify whether the prognosis of beast cancer is significantly correlated with IDO expression.